Revenue (Tables)

9 Months Ended

Jan. 23, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Net Sales by Segment and Division and by Market Geography

The table below illustrates net sales by segment and division and by market geography for the three and nine months ended January 23, 2026 and January 24, 2025. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.

	Worldwide
	Three months ended				Nine months ended
(in millions)	January 23, 2026		January 24, 2025		January 23, 2026		January 24, 2025
Cardiac Rhythm & Heart Failure	$	1,856	$	1,545	$	5,394	$	4,659
Structural Heart & Aortic	929		874		2,814		2,610
Coronary & Peripheral Vascular	672		618		1,971		1,876
Cardiovascular	3,457		3,037		10,179		9,145
Cranial & Spinal Technologies	1,310		1,250		3,819		3,632
Specialty Therapies	746		732		2,191		2,181
Neuromodulation	503		476		1,527		1,413
Neuroscience	2,558		2,458		7,536		7,226
Surgical & Endoscopy	1,654		1,596		4,945		4,790
Acute Care & Monitoring	519		476		1,483		1,406
Medical Surgical	2,173		2,072		6,428		6,196
Diabetes	796		694		2,274		2,027
Reportable segment net sales	8,985		8,260		26,417		24,593
Other operating segment(1)	32		32		101		106
Other adjustments(2)	—		—		39		(90)
Total net sales	$	9,017	$	8,292	$	26,557	$	24,610

	U.S.				International				U.S.				International
	Three months ended								Nine months ended
(in millions)	January 23, 2026		January 24, 2025		January 23, 2026		January 24, 2025		January 23, 2026		January 24, 2025		January 23, 2026		January 24, 2025
Cardiovascular	$	1,589	$	1,405	$	1,868	$	1,632	$	4,660	$	4,242	$	5,519	$	4,904
Neuroscience	1,709		1,689		849		769		5,063		4,931		2,474		2,295
Medical Surgical	929		893		1,244		1,180		2,756		2,718		3,671		3,478
Diabetes	248		236		548		457		695		683		1,579		1,344
Reportable segment net sales	4,475		4,223		4,510		4,038		13,174		12,573		13,243		12,020
Other operating segment(1)	18		15		14		17		60		51		41		55
Other adjustments(2)	—		—		—		—		—		—		39		(90)
Total net sales	$	4,493	$	4,237	$	4,524	$	4,055	$	13,234	$	12,624	$	13,323	$	11,986

(1)Includes operations and ongoing transition agreements from businesses the Company has exited or divested.

(2)Reflects adjustments to the Company's Italian payback accruals as further described below.